Literature DB >> 10926176

Hepatocyte growth factor in renal regeneration, renal disease and potential therapeutics.

K Matsumoto1, S Mizuno, T Nakamura.   

Abstract

Hepatocyte growth factor (HGF) has mitogenic, motogenic, morphogenic, and anti-apoptotic activities on renal cells and is a potential renotropin for renal protection and repair. In chronic renal failure/fibrosis, HGF in the kidney declines in a reciprocal manner to the increase in transforming growth factor-beta (TGF-beta). Neutralization of HGF by the antibody leads to acceleration of renal failure/fibrosis while HGF administration leads to remarkable attenuation, thus indicating the importance of HGF versus TGF-beta counterbalance in both pathogenesis and therapeutics in cases of chronic renal failure. HGF is being strongly considered for potential treatment of acute and chronic renal failure.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10926176     DOI： 10.1097/00041552-200007000-00011

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN： 1062-4821            Impact factor:   2.894


  8 in total

1.  Urinary biomarkers and renal recovery in critically ill patients with renal support.

Authors:  Nattachai Srisawat; Xiaoyan Wen; Minjae Lee; Lan Kong; Michele Elder; Melinda Carter; Mark Unruh; Kevin Finkel; Anitha Vijayan; Mohan Ramkumar; Emil Paganini; Kai Singbartl; Paul M Palevsky; John A Kellum
Journal:  Clin J Am Soc Nephrol       Date:  2011-07-14       Impact factor: 8.237

2.  Traction microscopy with integrated microfluidics: responses of the multi-cellular island to gradients of HGF.

Authors:  Hwanseok Jang; Jongseong Kim; Jennifer H Shin; Jeffrey J Fredberg; Chan Young Park; Yongdoo Park
Journal:  Lab Chip       Date:  2019-04-23       Impact factor: 6.799

3.  Combined paracrine and endocrine AAV9 mediated expression of hepatocyte growth factor for the treatment of renal fibrosis.

Authors:  Stephanie Schievenbusch; Ingo Strack; Melanie Scheffler; Roswitha Nischt; Oliver Coutelle; Marianna Hösel; Michael Hallek; Jochen W U Fries; Hans-Peter Dienes; Margarete Odenthal; Hildegard Büning
Journal:  Mol Ther       Date:  2010-04-27       Impact factor: 11.454

4.  Sustained expression of naked plasmid DNA encoding hepatocyte growth factor in mice promotes liver and overall body growth.

Authors:  J Yang; S Chen; L Huang; G K Michalopoulos; Y Liu
Journal:  Hepatology       Date:  2001-04       Impact factor: 17.425

5.  Overexpression of c-Met and CD44v6 receptors contributes to autocrine TGF-β1 signaling in interstitial lung disease.

Authors:  Shibnath Ghatak; Galina S Bogatkevich; Ilia Atnelishvili; Tanjina Akter; Carol Feghali-Bostwick; Stanley Hoffman; Victor M Fresco; John C Fuchs; Richard P Visconti; Roger R Markwald; Subhas B Padhye; Richard M Silver; Vincent C Hascall; Suniti Misra
Journal:  J Biol Chem       Date:  2013-12-09       Impact factor: 5.157

6.  Hepatocyte growth factor gene therapy enhances infiltration of macrophages and may induce kidney repair in db/db mice as a model of diabetes.

Authors:  M Flaquer; M Franquesa; A Vidal; N Bolaños; J Torras; N Lloberas; I Herrero-Fresneda; J M Grinyó; J M Cruzado
Journal:  Diabetologia       Date:  2012-03-30       Impact factor: 10.122

Review 7.  Regenerative medicine for the kidney: renotropic factors, renal stem/progenitor cells, and stem cell therapy.

Authors:  Akito Maeshima; Masao Nakasatomi; Yoshihisa Nojima
Journal:  Biomed Res Int       Date:  2014-05-08       Impact factor: 3.411

8.  Conditioned mesenchymal stem cells attenuate progression of chronic kidney disease through inhibition of epithelial-to-mesenchymal transition and immune modulation.

Authors:  Jei-Wen Chang; Hsin-Lin Tsai; Chang-Wei Chen; Hui-Wen Yang; An-Hang Yang; Ling-Yu Yang; Paulus S Wang; Yee-Yung Ng; Teng-Lung Lin; Oscar K Lee
Journal:  J Cell Mol Med       Date:  2012-12       Impact factor: 5.310
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.